Introduction
The NF-kB transcription factor is activated by a variety of extracellular signals and plays a crucial role in regulation of immune, in¯ammatory and antiapoptotic responses by activation of responsive genes (Baeuerle and Baltimore, 1996; Baldwin, 1996) . The NF-kB DNA binding protein is composed of homo-and heterodimeric complexes of the NF-kB/Rel family of proteins. To date, ®ve human genes encoding NF-kB/Rel proteins have been isolated and characterized. These proteins share the Rel-homology domain (RHD), a region of 300 amino-acids located in the N-terminus, containing sequences responsible for DNA-binding, dimerization and nuclear localization. In addition, the RelA, RelB and c-Rel proteins contain in their carboxytermini a strong transactivation domain. p50-NFkB1 and p52-NFkB2 are devoid of such domains and are generated by a co-translational mechanism and/or processing from a larger precursor (p105-NFkB1 and p100-NFkB2 respectively), containing the so-called ankyrin repeats in their C-terminal domains (Baeuerle and Baltimore, 1996; Baldwin, 1996; Lin et al., 1998) . The ankyrin motif is also found in the structurallyrelated IkB family of proteins (IkBa, IkBb, IkBe, Bcl-3, IkB-R, p105-NFkB1 and p100-NFkB2 in humans), involved in the regulation of the NF-kB transcription factor (Whiteside and IsraeÈ l, 1997) . In the vast majority of cells, the NF-kB complex is held in the cytoplasm in association with IkB inhibitor proteins which mask the nuclear localization signal (NLS) of the transcription factor (Baeuerle and Baltimore, 1996; Baldwin, 1996) . Following stimulation, signal-induced activation of the IkB kinases leads to phosphorylation of the IkBa protein on serine 32 and 36, which targets the molecule for rapid degradation via the ubiquitin proteasome pathway (Baldwin, 1996; Stancovski and Baltimore, 1997; Verma and Stevenson, 1997; Karin and Delhase, 1998) . This signal-induced degradation of IkBa allows release of the NF-kB transcription factor, which translocates to the nucleus and activates kB-dependent genes. Among these, transcription of the IkBa gene is rapidly induced and the newly synthesized IkBa protein accumulates in the nucleus where it is responsible for post-induction repression of NF-kB-dependent transcription (DeMartin et al., 1993; LeBail et al., 1993; Chiao et al., 1994; Arenzana-Seisdedos et al., 1995) .
It is therefore likely that deregulation of such a complex and tightly regulated system will have important consequences in the control of cell proliferation and oncogenesis. For instance, the ®rst isolated member of the NF-kB/Rel family, the acutely transforming v-rel retroviral oncogene induces fatal lymphomas in birds (Gilmore et al., 1995) . Rearrangement, ampli®cation, point mutation and/or overexpression of genes encoding NF-kB/Rel/IkB proteins, notably p100-NFkB2, c-Rel and Bcl-3, have been found in human cancers, mostly of lymphoid origin (Gilmore et al., 1996; Luque and Gelinas, 1997) . The constitutive activation of NF-kB by the viral Tax, LMP-1 and HBx proteins of the HTLV-I, EBV and HBV respectively, is thought to contribute to virallyinduced transformation (Mosialos, 1997) , as shown by the blockade of Tax-induced tumorigenesis in vivo by antisense to RelA (Kitajima et al., 1992) .
Constitutive activation of NF-kB has been reported in Hodgkin's disease (Gruss et al., 1992; Bargou et al., 1996) , a distinct group of lymphomas, characterized by a low frequency of the Hodgkin and Reed ± Sternberg malignant cells in a reactive background of nonneoplastic cells. The peculiar activated phenotype of H/RS cells and their pattern of cytokine secretion, which contribute to the pathological appearance and clinical manifestations of the disease, is believed to be a consequence of constitutive NF-kB activation (Gruss and Kadin, 1996; Gruss et al., 1997) . In approximately one-third of HD cases, H/RS cells are EBV-infected and express the LMP-1 protein, therefore providing an explanation for constitutive activation of NF-kB (Gruss and Kadin, 1996; Gruss et al., 1997; Mosialos, 1997) . The recent observation that tumour growth of HD-derived cell lines in severe-combined immunode®cient mice was strongly impaired when NFkB was inhibited, indicates that activation of the transcription factor is contributing to the transformed phenotype (Bargou et al., 1997) . To characterize the molecular basis for this constitutive NF-kB activation, we describe in this paper, the ®rst isolated mutations of the IkBa gene in two HD-derived cell lines and in a biopsy sample from a patient with relapsed EBVnegative HD. Our results strongly suggest that IkBa is a tumour suppressor controlling the oncogenic activation of the NF-kB/Rel family of proto-oncoproteins.
Results

Aberrant IkBa protein in Hodgkin's disease-derived cell lines
The high constitutive nuclear activation of NF-kB has emerged as a characteristic feature of HD-derived cell lines as well as primary tumour cells. This activity has been attributed mainly to the classical p50/RelA NFkB heterodimer (Gruss et al., 1992; Bargou et al., 1996 Bargou et al., , 1997 Wood et al., 1998) . Using ®ve well-characterized Hodgkin's disease cell lines, we have analysed the expression of IkBa, -b and -e proteins (Baeuerle and Baltimore, 1996; Baldwin, 1996; Whiteside and IsraeÈ l, 1997) . As reported previously (Wood et al., 1998) , we were unable to detect the IkBa protein in KM-H2 cells, but, when cells were pre-treated with the proteasome inhibitor Z-LLL-H a faster migrating species of 18 kDa was detected (Figure 1) . In L-428 cells a product of 30 kDa accumulates in the presence of the proteasome inhibitor (Figure 1 ). An IkBa protein of apparently normal size was detected in HDLM-2, L-540 and L-591 cells (Figure 1 ). When these cells were pre-treated with the proteasome inhibitor, a band of slightly slower electrophoretic mobility, corresponding to the inducedphosphorylated form of the protein was detected on more highly resolving gels (data not shown). This observation indicates that the signal-induced degradation pathway of the IkBa protein is constitutively activated in these cells (Baeuerle and Baltimore, 1996; Baldwin, 1996) . As shown in Figure 1 , using an antibody recognizing the N-terminus of the IkB-b protein, we could detect both IkB-b 1 (slower migrating) and IkB-b 2 (faster migrating) isoforms (Hirano et al., 1998) in all HD-derived cell lines investigated. Finally, although IkBe was present in most Hodgkin's diseasederived cell lines, L-428 cell extracts prepared in dierent conditions consistently failed to show any reactivity (E Cabannes and RT Hay, manuscript in preparation).
Mutant IkBa mRNA in KM-H2 and L-428 cells
To determine the molecular basis for these observations, we characterized the IkBa mRNA expression in Figure 1 Expression of IkBa, -b and -e proteins in Hodgkin's disease-derived cell lines. Twenty mg of whole cell extracts, from indicated cell lines incubated for 2 h with the proteasome inhibitor Z-LLL-H (20 mM; right panels) or with the solvent as control (DMSO, left panels), were analysed by Western blotting using antibodies speci®c for each IkB species (see Materials and methods). a-Tubulin was used as a loading control. The slower and faster migrating bands detected with the anti-IkBb antibody correspond to the IkB-b 1 and IkB-b 2 isoforms, respectively HD-derived cell lines. Consistent with the observation that the IkBa gene expression is under the control of NF-kB (DeMartin et al., 1993; LeBail et al., 1993; Chiao et al., 1994) , we found that the steady-state level of the IkBa transcript is signi®cantly increased in Hodgkin's disease-derived cell lines compared to Jurkat and Daudi cells ( Figure 2a ; Bargou et al., 1996; Wood et al., 1998) . Using primers which amplify the IkBa coding sequence, poly(A) + RNA from HD-derived cell lines was analysed by RT ± PCR (Figure 2b ). Sequence analysis of the shorter KM-H2 reverse transcript revealed a deletion from nucleotide 509 ± 641 (numbering from Haskill et al., 1991) , replaced by an insertion of the pentanucleotide 5'-TCCAG-3' (Figure 3e ). This transcript encodes a 164 amino acid polypeptide containing IkBa residues 1 ± 138, followed by an out of frame 26 amino acid sequence. Although the L-428 reverse transcript co-migrated with the wild-type product observed in others cell lines, its sequence diers by a single point mutation, a C to T transition, in position 893 (Haskill et al., 1991) . This mutation is of dramatic consequence as it creates a stop codon after residue 266 of IkBa ( Figure 3d ). As expected, sequence analysis of IkBa reverse transcripts in HDLM-2, L-540 and L-591 cells revealed that they encode a wild-type product. The sequence of the faster migrating species observed in HDLM-2 cells ( Figure  2b ), indicates that it derives from the wild-type product by alternative splicing, using an alternative acceptor site located in the downstream exon (dinucleotide AG positions 858 ± 859 in Haskill et al., 1991 ; see also Ito et al., 1995) . This cDNA encodes an IkBa variant of 274 amino-acids, lacking residues 213 ± 255, and deleted of the ®fth ankyrin repeat. The physiological relevance of this observation is unclear, as we were unable to detect such an isoform in HDLM-2 cell extracts (see Figure  1 ), probably due to extremely low levels of the transcript.
KM-H2 and L-428 IkBa mutant mRNAs encode the 18 and 30 kDa defective IkBa proteins observed in cellular extracts
The predicted size of the IkBa mutant proteins deduced from the sequence of the KM-H2 and L-428 cDNAs (164 and 266 amino acids, respectively), correlated well with the size of the defective IkBa proteins detected in these cells (18 and 30 kDa, respectively; see Figure 1 ). To con®rm that these transcripts encoded the defective IkBa species, cDNAs were in vitro transcribedtranslated and submitted to a co-migration experiment on SDS ± PAGE with corresponding whole cell extracts. The Western blot shown in Figure 2c , indicates that the defective IkBa proteins detected in KM-H2 and L-428 extracts result from translation of the mutant IkBa transcripts isolated in these cells. IkBa can be divided into three structural domains: a N-terminal region, an internal region composed mainly of ankyrin repeats and a C-terminal region containing a so-called PEST region. Protease sensitivity studies have shown that the integrity of the C-terminal region is essential for interaction with and inhibition of the RelA subunit of NF-kB (Jaray et al., 1995) . Deletion of this domain in KM-H2 and L-428 IkBa mutant proteins, indicates that IkBa activity has been lost in these cells, and consequently is likely to account for constitutive NF-kB activation.
IkBa alleles are mutated in KM-H2 and L-428 cell lines
In view of our previous results, the IkBa alleles in KM-H2 and L-428 cells were characterized. To demonstrate the presence of the point mutation in genomic DNA from L-428 cells, PCR analysis using Taq DNA polymerase, which lacks a proofreading exonuclease activity (Promega, WI, USA), was conducted with a wild-type or a mutant primer containing the L-428 mutation at its 3' end and a common downstream primer. The L-428 IkBa allele is ampli®ed with the mutant but not the wild-type primer, whereas the IkBa allele in Daudi cells is ampli®ed with the wild-type but not the mutant primer (Figure 3a) . Direct comparison indicated that the PCR product ampli®ed in L-428 cells had a slightly greater electrophoretic mobility than the 585 nucleotides wild-type species from Daudi cells. DNA sequence analysis of this product revealed it has a deletion of 19 nucleotides (position 2555 ± 2573 in Ito et al., 1995) , in the intron joining exons 5 and 6 ( Figure  3d ). The absence of the wild-type PCR product and the presence of at least two mutations in the L-428 allele strongly suggest that the other copy has been deleted. Thus, L-428 cells do not contain a wild-type IkBa allele and the defective IkBa protein detected in cellular extracts is the gene product of the mutant allele.
To demonstrate a deletion in the KM-H2 IkBa allele a similar type of experiment, using primers¯anking the IkBa cDNA deletion observed in these cells, was carried out. Direct DNA sequence analysis of the PCR products detected in Figure 3b , clearly demonstrates a deletion in the KM-H2 IkBa allele. This 214 nucleotide deletion extends from nucleotide 1497 (position 509 in Haskill et al., 1991) to 1710 ( Figure  3d ; Ito et al., 1995) . No wild-type allele was detected in these cells. To unambiguously exclude the possibility of a wild-type IkBa allele in KM-H2 cells, we performed Southern blot analysis, shown in Figure 3c . The pattern obtained when genomic DNA was digested by SacI or HindIII restriction enzymes, using Jurkat cells as a control, clearly rules out such a possibility. Although the 3' end of the intron joining exons 3 and 4 had been deleted, the remaining sequence of this intron was absent in the cDNA, suggesting that an alternative splice mechanism was occurring. Indeed, on the 3' side of the deletion we found an alternative donor splice site with the exceptional GC dinucleotide (5'-CAG/ GCAAGA-3'), ®tting almost perfectly the consensus sequence described by Hoeijmakers and colleagues (Troelstra et al., 1993) for this type of donor splice sites (5'-CAG/GCAAGT-3'). This splicing event would not only explain the removal of the remaining intronic sequence but also the presence of the 5'-TCCAG-3' pentanucleotide sequence in the cDNA. The mechanism which generates the 18 kDa defective IkBa protein from the deleted IkBa allele in KM-H2 cells is summarized in Figure 3e . In conclusion, as already mentioned for the L-428 cell line, we showed that KM-H2 cells do not contain a wild-type IkBa allele and the defective IkB-a protein detected in these cells is the gene product of a mutant allele.
Detection of an IkBa allele mutation in a biopsy sample from a Hodgkin's disease patient
The observation that two Hodgkin's disease-derived cell lines were carrying mutations in the IkBa gene strongly suggested it has a crucial role in oncogenesis. To con®rm the pathological relevance of this observation, we screened for IkBa mutations in biopsy samples from a group of four Hodgkin's disease patients. Hodgkin and Reed-Sternberg cells were enriched using CD30 as a selection marker (Gruss and Kadin, 1996; Gruss et al., 1997) . The¯ow cytometric analysis of the CD30-enriched fraction from a lymph node of a 40-year-old female (patient 3717), with relapsed EBVnegative Hodgkin's disease of nodular sclerosis subtype, indicated it contained 42.3% CD30+ cells (Figure 4a ). This value is likely to be an over-estimate of the abundance of H/RS cells, as the CD30 marker is not exclusive to these cells, but also expressed on (Gruss and Herrmann, 1996) . Scatter plot analysis of CD30-positivity in relation to the size of the cells, shows that the enriched fraction contains 20.6% cells which are both large and CD30+ ( Figure  4a ), this population most likely represents the H/RS cells. The CD30+ large cells represent less than 3% of the CD30-depleted fraction, a value similar to that obtained for pre-fractionated cells from this case (Figure 4a and data not shown) . Nested PCR analysis using primers located in exons 2 and 6 of the IkBa gene was carried out on these fractions (Figure 4b) . In addition to the 1.7 kb species corresponding to the wild-type allele, which was ampli®ed in both fractions, a 0.9 kb species was speci®cally ampli®ed in the CD30-enriched fraction. Sequence analysis of this product revealed a deletion from nucleotide 1135 ± 1990 ( Figure  4c ; Ito et al., 1995) . This deletion (from amino acid 113 ± 212) would remove ankyrin repeats 2, 3 and part of 4 from the IkBa protein thus rendering it incapable of interacting with NF-kB and thus constitutively activating NF-kB-dependent transcription. The relatively low intensity of the deleted PCR product compared to the abundance of H/RS cells in the CD30-enriched fraction, indicates that this mutation is only present in a subpopulation of malignant cells.
Nested PCR analysis recently being carried out on another four biopsy samples following CD15 enrichment also revealed a case with an IkBa deletion from exon 2 to exon 6 (G Khan and RF Jarrett, to be published elsewhere).
Discussion
Since the original discovery of the retroviral oncoprotein v-rel, which induces fatal lymphomas in birds within 7 ± 14 days (Gilmore et al., 1995) , members of the NF-kB/Rel family have been suspected of playing a role in the control of cell proliferation and oncogenesis. Indeed, the involvement of the NF-kB/Rel and IkB proteins in the development of cancer in humans, primarily of lymphoid origin, has since been con®rmed on several occasions (Gilmore et al., 1996; Luque and Gelinas, 1997; Mosialos, 1997) . Multiple cellular and viral activators of NF-kB act via signal-induced degradation of IkB proteins (Baeuerle and Baltimore, 1996; Baldwin, 1996) . A unique role for IkBa in NF-kB regulation is indicated by the constitutive nuclear activation of NF-kB in hematopoietic tissues from IkBa knockout mice (Beg et al., 1995) . Our ®ndings also suggest that constitutive NF-kB activation in Hodgkin's disease-derived cell lines is a consequence of defective IkBa. Although wild-type IkBa is present in HDLM-2, L540 and L-591 cell lines it appears that the signal transduction pathway leading to IkBa proteolysis is constitutively active (E Cabannes and RT Hay, unpublished results). In L591 cells this is likely to be due to the presence of the EBV LMP-1 protein (Drexler, 1993; Sylla et al., 1998) . Here we describe mutations in the IkBa gene in two HD-derived cell lines (KM-H2 and L-428), and also in biopsy samples from two out of eight patients with relapsed EBVnegative HD. These data explain our previous observations on HD-derived cell lines where defective IkBa proteins were detected (Wood et al., 1998) . The presence of truncated IkBa in KM-H2 and L-428 cells has recently been con®rmed by others (Krappmann et al., 1999) , but it remains dicult to explain the reported presence of full length IkBa protein in KM-H2 cells (Bargou et al., 1996) . Although analysis on a wider sample is needed to estimate the prevalence of IkBa deletion in Hodgkin's disease, our PCR strategy which would not detect point mutations or a complete deletion of the gene, is likely to underestimate the real frequency of this event in HD.
The potential role for IkBa in cellular transformation has been suggested but is a matter of some debate. For instance, antisense expression of IkBa has been reported to transform the mouse NIH3T3 cell line (Beauparlant et al., 1994) , suggesting that NF-kB activation induces transformation. However, homozygous inactivation of the IkBa gene in mice is not tumorigenic and ®broblast cell lines established from these mice are not transformed (Beg et al., 1995; Klement et al., 1996) . Cells isolated from patients with ataxia telangiectasia have a high level of IkBa expression but have constitutive nuclear NF-kB activity, which is inhibited by expression of a dominant-negative form of IkBa (Jung et al., 1995) . Although the NF-kB/Rel proteins and their IkB regulatory subunits are ubiquitously expressed, the nature of the eects induced by modulation of NF-kB activity are likely to vary depending on the expression levels of these dierent signal transduction factors and also on the dierentiation and proliferation states of the cell type in which these events are occurring.
The observation that activation of the NF-kB family of transcription factors can protect most cell types from apoptosis (Sonenshein, 1997) , may indicate that the role of NF-kB in oncogenesis is to enhance the viability of tumour cells. A consistent observation was recently described in HD-derived cell lines, where tumour growth in severe-combined immunode®cient mice was strongly impaired when NF-kB activity was inhibited (Bargou et al., 1997) . Mutations rendering the IkBa proteins incapable of interacting with NF-kB and thus resulting in loss of IkBa activity are likely to contribute to the transformed phenotype of Hodgkin's disease by enhancing the viability of H/RS cells. We describe in this paper, the ®rst isolated mutations of the IkBa gene in two HD-derived cell lines and in a biopsy sample from a patient with relapsed EBVnegative HD.
Our results, strongly suggest that IkBa is a tumour suppressor controlling the oncogenic activation of the NF-kB/Rel family of proto-oncoproteins. Despite considerable progress in treatments, about 30% of Hodgkin's disease patients still die from the disease (Diehl, 1996) . The identi®cation of the IkBa protein as a potential target constitutes a signi®cant step forward in developing therapeutic treatments for Hodgkin's disease.
Materials and methods
Cell culture
Five HD-derived cell lines were used for these experiments. The KM-H2, HDLM-2 and L-428 cell lines were obtained from the DSMZ cell line collection (Braunschweig, Germany), the L-540 and L-591 cell lines were kindly provided by Dr Katrina Wood (Newcastle, UK). Cell lines were grown in RPMI 1640 (ICN Biomedicals, UK) supplemented with 2 mM Glutamine (ICN Biomedicals, UK) and 5% (Jurkat), 10% (Daudi, KM-H2, L-428, L-540, L-591) or 20% (HDLM-2) heat inactivated foetal calf serum (Labtech International, UK) at 378C in a 5% CO 2 atmosphere.
Enrichment of Reed ± Sternberg cells
Hodgkin and Reed ± Sternberg cells were enriched from an aected lymph node of a 40-year-old female with relapsed EBV-negative HD of nodular sclerosis subtype, using magnetic cell sorting (MiniMACS; Miltenyi Biotec, UK). Brie¯y, the lymph node was disrupted and cells fractionated on Ficol-Hypaque (Pharmacia, UK). After washing mononuclear and H/RS cells were resuspended in foetal calf serum containing 8% DMSO and stored in liquid nitrogen.
For enrichment, H/RS cells were labelled with anti-CD30-FITC monoclonal antibody (clone Ber H2; Dako, UK), followed by anti-FITC-Magnetic MicroBeads (Miltenyi Biotec, UK). The washed cell suspension was passed through a column placed in a magnetic ®eld and unbound cells were allowed to¯ow through (CD30-depleted fraction). After several washes, the column was removed from the magnetic ®eld and the CD30-enriched fraction¯ushed out. Purity of CD30-enriched cells was determined by¯ow cytometry using an EPICS Elite instrument (Coulter Electronics, UK).
In vitro transcription-translation and Western blot analysis
Cells were incubated with the proteasome inhibitor Z-LLL-H for 2 h at a ®nal concentration of 20 mM or with the solvent as control (DMSO). After washing, cells were lysed in SDS loading buer (50 mM Tris-HCl pH 6.8, 100 mM DTT, 2% SDS, 0.1% Bromophenol Blue, 10% Glycerol). Cell proteins were resolved by SDS ± PAGE, transferred to Immobilon-P PVDF membranes (Millipore, MA, USA) and probed with the 10B monoclonal IkBa (Jaray et al., 1995) , the IkBb (N-20; Santa Cruz, CA, USA), the IkBe (M-121; Santa Cruz, CA, USA), or the a-tubulin (Amersham Life Science, UK) antibodies. Anti-mouse or anti-rabbit HRP-conjugates were detected using ECL (Amersham Life Science, UK). IkBa cDNAs generated by reverse transcription of mRNA from Daudi (WT), L-428 and KM-H2 cells were cloned into pBluescript SK (Stratagene, CA, USA), and linearized DNA was in vitro transcribed-translated using the TnT T7 Coupled Wheat Germ Extract System (Promega, WI, USA). Reactions were stopped by addition of one volume of 26 SDS loading buer and translated products resolved by SDS ± PAGE.
Northern and Southern blotting
Total cell RNA and genomic DNA were isolated using the RNeasy and QIAamp Blood kits according to the manufacturer's protocols (QIAGEN, CA, USA). Total RNA (10 mg) was separated on a 1% agarose gel containing formaldehyde, transferred onto a BA85 nitrocellulose membrane (Schleicher & Schuell, Germany) and probed with radiolabelled IkBa and Glyceraldehyde-3'-phosphate dehydrogenase (GAPDH) cDNAs. Ten mg of digested genomic DNA was separated on a 1% agarose gel, denaturated and transferred onto a BA85 nitrocellulose membrane (Schleicher & Schuell, Germany) . Membranes were probed with radiolabelled IkBa cDNA using standard procedures. After washing blots were exposed to Phosphorimaging Plates and radioactivity detected using the Fujix Bas 1500 Phosphorimager (Fuji, Japan).
RT ± PCR and PCR analysis
Poly(A) + RNA from HD-derived cell lines was isolated using the Oligotex Direct mRNA kit (QIAGEN, CA, USA).
